Humana (HUM)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-14
$407.02-0.68%
Close 2026-09-14 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-14
Research Workspace
Put HUM beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain EPS guidance of at least $9.00 for FY 2026: EPS guidance $9.00 vs $9.00 target.
View ThesisRevenue growth is accelerating — up about 18% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 45% in its worst 12-month stretch.
View RiskHUM's growth relies on maintaining its EPS guidance of at least $9.00 for FY 2026. Recent financial performance shows strong revenue growth of 26% year over year, with the latest quarter beating expectations. HUM trades at 24× P/E versus a peer median of 22×, indicating it looks expensive based on current multiples. The primary risk is the lowered EPS guidance, which puts pressure on the growth outlook. Peer multiples imply a price about 6% below where it trades. Our read remains intact.
Trailing returns as of 2026-09-14. HUM is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 26 analysts currently covering HUM (as of Sep 2026).
Based on 19 Wall Street analysts offering 12-month price targets for HUM in the last 4 months.
Continue this research
Compare HUM with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HUM Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Managed Health Care — fair value, gap to price, and forward P/E.
Compare the value case
Put HUM next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Cuts could negatively affect Medicare Advantage Star Ratings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $407.02
The last 12 months of price, then the range of analyst 12-month targets from today’s $407.02.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Potential loss of Medicare Advantage members impacts Star Ratings.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Tightening margins could impact Medicare Advantage profitability.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Medicare Advantage plans dropping could impact Star Ratings management.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Dropping plans may negatively impact Medicare Advantage business.
Advances: Maintain FY 2026 Adjusted EPS guidance of at least $9.00
Upgrades suggest confidence in margin recovery and EPS growth.
Threatens: Manage impact of Star Ratings on Medicare Advantage business
Ending plans may negatively impact Star Ratings and membership.
Advances: Manage impact of Star Ratings on Medicare Advantage business
Operational progress supports Medicare Advantage strategy.